These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 24425322)
1. Rising CEA levels in a patient with colon carcinoma: metachronous medullary thyroid cancer. Göksu SS; Göksu UA; Gündüz S; Coskun HS Int J Biol Markers; 2014 Jun; 29(2):e184-6. PubMed ID: 24425322 [TBL] [Abstract][Full Text] [Related]
2. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer. Chen SW; Chen YK World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496 [TBL] [Abstract][Full Text] [Related]
3. F-18 FDG PET detection of a medullary thyroid carcinoma in a patient with metastatic colonic cancer; literature review. Cohen R; Bihan H; des Guetz G; Wind P; Martin A Ann Endocrinol (Paris); 2009 Dec; 70(6):468-72. PubMed ID: 19744643 [TBL] [Abstract][Full Text] [Related]
4. Carcinoembryonic Antigen Increase in a Patient with Colon Cancer Who Have Achieved Complete Remission and Negative Lugat A; Hulo P; Ansquer C; Touchefeu Y; Mirallié E; Bennouna J; Drui D Curr Oncol; 2021 Aug; 28(4):2987-2992. PubMed ID: 34436027 [TBL] [Abstract][Full Text] [Related]
5. Persistent elevation of carcinoembryonic antigen as first presentation of a medullary thyroid carcinoma. Martins A; Gonçalves A; Almeida T; Midões A BMJ Case Rep; 2018 Jun; 2018():. PubMed ID: 29895542 [TBL] [Abstract][Full Text] [Related]
6. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer. Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887 [TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases. Mucha SA; Kunert-Radek J; Pomorski L Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852 [TBL] [Abstract][Full Text] [Related]
8. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749 [TBL] [Abstract][Full Text] [Related]
9. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review. Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-up in Medullary Thyroid Carcinoma. Raue F; Frank-Raue K Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391 [TBL] [Abstract][Full Text] [Related]
11. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level. Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474 [TBL] [Abstract][Full Text] [Related]
12. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. Mitchell AL; Gandhi A; Scott-Coombes D; Perros P J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128 [TBL] [Abstract][Full Text] [Related]
13. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128 [TBL] [Abstract][Full Text] [Related]
14. Metastasis of colon cancer to medullary thyroid carcinoma: a case report. Yeo SJ; Kim KJ; Kim BY; Jung CH; Lee SW; Kwak JJ; Kim CH; Kang SK; Mok JO J Korean Med Sci; 2014 Oct; 29(10):1432-5. PubMed ID: 25368499 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA. Gade M; Kubik M; Fisker RV; Thorlacius-Ussing O; Petersen LJ Cancer Imaging; 2015 Aug; 15(1):11. PubMed ID: 26263901 [TBL] [Abstract][Full Text] [Related]
16. F-18 FDG PET demonstration of a thyroid metastasis in a patient with colon cancer. Iguchi T; Matsuoka J; Sato S; Okumura Y; Omori M; Mifune H; Akaki S; Kanazawa S Clin Nucl Med; 2007 May; 32(5):361-2. PubMed ID: 17452862 [TBL] [Abstract][Full Text] [Related]
17. A high level of carcinoembryonic antigen as initial manifestation of medullary thyroid carcinoma in a patient with subclinical hyperthyroidism. Akbulut S; Sogutcu N Int Surg; 2011; 96(3):254-9. PubMed ID: 22216705 [TBL] [Abstract][Full Text] [Related]
18. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Machens A; Ukkat J; Hauptmann S; Dralle H Arch Surg; 2007 Mar; 142(3):289-93; discussion 294. PubMed ID: 17372055 [TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh B; Kapoor R; Gupta R Nucl Med Commun; 2011 Sep; 32(9):789-93. PubMed ID: 21760561 [TBL] [Abstract][Full Text] [Related]
20. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues. Cano JM; Galán R; López R Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]